Diary Of A Psychedelic Executive
Since we listed Psyence on the Canadian Securities Exchange (CSE) in January 2021, we have commenced cultivation, started research and development, and recruited extraordinary medical and scientific talent to collaborate in finding psychedelic-assisted solutions to the current mental health crisis. The enduring work of Psyence is to develop and provide innovative, safe and responsible psychedelic and nature-based solutions for mental health and mental wellness that heal, open consciousness, and nurture community.
This is a unique time in the history of medicine and pharmaceutical drug development and that is why we launched “The Diary of a Psychedelic Exec.”
If you are an investor or interested in psychedelic healing and what Psyence is up to, then please join us each week as we share the work of building a sustainable business that delivers shareholder value.
– Jody Aufrichtig, Co-founder and Executive Chairman, Psyence
We value your feedback – diary@psyence.com
Investor News
The Diaries of a Psychedelic Exec : Episode 8
This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.
The Diaries of a Psychedelic Exec : Episode 7
Dr Amza Ali is a neurologist and the global medical director at Psyence. In this episode of the Diary of a Psychedelic Exec, Dr Ali shares his thoughts on palliative care, a key focus area for Psyence.
Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products
We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.
The Diaries of a Psychedelic Exec : Episode 6
Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.
The Diaries of a Psychedelic Exec : Episode 5
It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.
Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial
Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.
Investor News
The Diaries of a Psychedelic Exec : Episode 8
This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.
The Diaries of a Psychedelic Exec : Episode 7
Dr Amza Ali is a neurologist and the global medical director at Psyence. In this episode of the Diary of a Psychedelic Exec, Dr Ali shares his thoughts on palliative care, a key focus area for Psyence.
Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products
We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.
The Diaries of a Psychedelic Exec : Episode 6
Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.
The Diaries of a Psychedelic Exec : Episode 5
It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.
Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial
Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.
Why Psyence?
International expertise in palliative medicine and science
- Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
- Our Scientific Advisory Board is led by Dr. Neil Maresky, vice president of Scientific affairs at Astra-Zeneca Canada
Extensive networks and partnerships
- We are building partnerships with a network of institutions and companies including:
- Government research centres
- University hospitals and research centres
- Regulatory stakeholders
- Clinics, retreats and hospitality centres
- Non-governmental organizations (NGOs)
An IP portfolio in cultivation and therapeutic products
- A mix of certified spores under cultivation
- Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
- Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)
Downloads
Financial Statements
Corporate Details
Why Psyence?
International expertise in palliative medicine and science
- Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
- Our Scientific Advisory Board is led by Dr. Neil Maresky, vice president of Scientific affairs at Astra-Zeneca Canada
Extensive networks and partnerships
- We are building partnerships with a network of institutions and companies including:
- Government research centres
- University hospitals and research centres
- Regulatory stakeholders
- Clinics, retreats and hospitality centres
- Non-governmental organizations (NGOs)
An IP portfolio in cultivation and therapeutic products
- A mix of certified spores under cultivation
- Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
- Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)
Investor Sign-Up
Please enter your details below to receive investor updates on Psyence Group